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SIGNIFICANCE
Cutaneous squamous cell carcinoma is one of the most 
common cancers of the skin. A more precise and timely 
knowledge of these tumours is needed in order to provide 
optimal care. This study describes the epidemiology of cu-
taneous squamous cell carcinomas in a patient cohort in 
Finland, analysing the anatomical distribution, histopatho-
logical features and treatment modalities to reflect the ty-
pical day-to-day clinical practice. 
The incidence of cutaneous squamous cell carcinoma is 
increasing worldwide. In most epidemiological studies, 
only the first case of cutaneous squamous cell carci-
noma is registered, underestimating the burden of the 
disease. To determine the frequency and detailed cha-
racteristics of cutaneous squamous cell carcinoma in a 
Finnish patient cohort, we performed a retrospective 
10-year study taking into account multiple tumours 
in one patient. On the pathology database search and 
medical record review we identified 774 patients with 
a total of 1,131 cutaneous squamous cell carcinomas. 
The crude incidence increased from 18.6/100,000 per-
sons in 2006 to 28.1 in 2015. The location of tumours 
differed between men and women: the greatest diffe-
rence concerned cutaneous squamous cell carcinoma 
of the ear, with 93% of cases occurring in men. One 
fourth (24%) of patients had more than one tumour. A 
small shift from poorly to well-differentiated tumours 
was seen. In conclusion, the incidence of cutaneous 
squamous cell carcinoma increased, with many pa-
tients presenting with multiple tumours.
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Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers of the skin. Although 
rarely fatal (1), cSCC reduces the quality of life of pa-
tients through functional impairment and severe cosmetic 
and psychosocial sequelae (2, 3). The incidence of cSCC 
is increasing in white populations worldwide (4). Thus, 
cSCCs have a substantial and increasing impact on 
healthcare costs (5). Most cSCCs occur in people aged 
60 years or older (6), a population expanding rapidly in 
aging societies in the near future. Consequently, cSCCs 
are creating an increasing demand on healthcare systems 
due to restricted resources (5, 7).
Although the burden of disease caused by cSCC is 
known to increase, the available registry data on cSCC 
epidemiology may still underestimate its impact on the 
healthcare systems (4, 8). In most epidemiological stu-
dies, only the first case of cSCC in a patient is registered 
while subsequent and multiple tumours are not taken 
into account (4). For future planning, a more precise and 
timely knowledge of cSCC epidemiology and tumour 
characteristics is needed for optimal patient care (7). 
We carried out a retrospective 10-year study to deter-
mine the frequency and characteristics of all detected and 
treated cSCCs in a Finnish regional university hospital 
cohort. Finland is a Nordic country with approximately 
5,5 million inhabitants of whom 30% have Fitzpatrick’s 
skin phototypes I or II and 60% type III (9). We have 
analysed the anatomical distribution, histopathological 
features and treatment modalities to reflect typical day-
to-day clinical practice in patients with cSCC, including 
those with multiple tumours. 
METHODS
The pathology database of Fimlab Laboratories was searched for 
the histopathologic diagnosis of ‘cutaneous squamous cell carci-
noma’ between 1 January 2006 and 31 December 2015. Fimlab 
provides the laboratory services in Pirkanmaa region of Finland, 
meaning that all patients with a cSCC diagnosis in the region were 
identified. In situ cSCC were excluded. We reviewed the clinical 
records of Tampere University Hospital, which is the region’s 
largest hospital and the tertiary referral centre of Pirkanmaa, for 
all identified cSCC patients. Data regarding demographic factors, 
including patient age at diagnosis of the primary tumour, sex 
and associated diseases, particularly immunosuppression, were 
registered. If the clinical notes indicated that the patient had cSCC 
before year 2006, this was registered.
Features of the tumours including the anatomic localisation, 
differentiation and depth of invasion were obtained. Degree of 
differentiation was classified either as well, moderate or poorly. 
Diagnostic duplicates, i.e. tumours first biopsied and then (re-)
excised, were taken into account and reassessed to identify the 
actual number of primary cSCCs. Patients with multiple primary 
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cSCCs diagnosed in the study period were included, and each case 
of cSCC was analysed separately. The histopathological features 
of each cSCC were based on the pathology reports of both the 
biopsy and the surgical excision specimen, using the sample with 
the poorest differentiation and the deepest invasion depth of the 
tumour. Based on the clinical notes, the tumours were assigned to 
one of the following 10 anatomic sites: lip, eyelid, ear, face (which 
excluded the 3 aforementioned sites), scalp and neck, trunk, upper 
extremity, lower extremity, anogenital area or oral cavity. 
The treatment method was recorded in each case. The clearance 
of microscopic surgical margins, i.e. the excision borders free of 
tumour cells to the edge (lateral resection margins) and to the 
bottom (deep resection margins) was recorded in millimetres 
(mm). Results of radiological imaging i.e. X-ray, ultrasonography, 
computed tomography examinations performed due to cSCC were 
registered.
Statistics
The demographic variables and clinical data of the cSCCs were 
assessed using descriptive statistics and frequency tabulation. For 
the crude incidence calculations, annual population numbers of 
Pirkanmaa region (situated at latitudes around 61°N) were obtained 
from the Official Statistics of Finland (10). In 2006 (beginning 
of the study period), the population of Pirkanmaa was 473,490 
and in 2015 (last year of the study), 506,114. The annual crude 
incidence rates were expressed as the number of cSCC cases per 
100,000 people. The numerator of the incidence rate was the 
number of cSCC diagnosed each calendar year, independent of 
the number of patients. Thus, a patient could be counted more 
than once a year if we were certain that the new tumours were 
not residual or recurrent.
Categorical data were described by number of patients with 
percentages. Differences between the categorical variables were 
tested by Pearson chi-square test or Fisher’s exact test. The analy-
ses were carried out using IBM SPSS Statistics for Windows, Ver-
sion 23.0 software (IBM Corp., Armonk, NY). Due to the skewed 
distributions, continuous variables were shown by medians with 
ranges and differences between the two distributions were tested by 
Mann-Whitney test. Statistical analysis were performed using IBM 
SPSS Statistics version 23. Trends in the time period were tested 
by Single ordered Kruskall-Wallis test or Cochran-Armitage trend 
test using StatXact-4 version 4.0.1 (Cytel Software Corporation).
The institutional review board of Tampere University Hospital, 
Finland approved this retrospective study.
RESULTS
The pathology database search yielded 1,698 cases of 
invasive (non-in situ) cSCCs. After the medical record 
review, 567 diagnostic duplicates, i.e. overlapping data 
on biopsy and excision of the same case of cSCC, were 
excluded, leaving 1,131 tumours in 774 patients in the 
study cohort. The annual number of cSCCs has risen 
during the study period from 88 (51 in men and 37 in 
women) in 2006 to 142 (91 in men and 51 in women) 
in 2015. The crude incidence (per 100,000 persons) in-
creased from 18.6 in 2006 to 28.1 in 2015 (Fig. 1). No 
significant difference between men (22.0 to 36.6) and 
women (15.3 to 19.8) was found (p = 0.722). 
Most cSCC cases were detected in people aged 80–89 
years. The annual number of cSCC rose, especially in 
people aged 85 years or older. Also the age-specific in-
cidence increased with age (Fig. 2). The median age of 
cSCC patients was 78 (range 39–100) years in men and 
83 (range 16–99) years in women. The age distribution of 
patients differed in men and women (p < 0.001) (Table I).
During the study period, 588 patients (76.0%) had one 
cSCC, 116 (15.0%) had two cSCCs and 70 (9.0%) had 
3 or more cSCCs (Table I). Total of 77 (9.9%) patients 
have been treated for cSCC before the start of the study 
period. Immunosuppression was present in 81 (10.5%) 
patients, due to organ transplantation (n = 37), rheuma-
toid arthritis (n = 23), chronic leukaemia (n = 10) and 
lymphoma (n = 11). Of the organ transplant recipients, 8 
patients had a heart transplant, 26 kidney transplant and 3 
liver transplant. None of the patients had HIV, and none 
had  received treatment with BRAF inhibitors. Out of 
all 1,131 tumours, 191 (16.9%) cSCCs were diagnosed 
in the immunosuppressed patients. These patients had 
a median of two (interquartile range [IQR] 1–6, range 
1–26) tumours per patient during the study period, while 
the immunocompetent patients had a median of one (IQR 
1–2, range 1–9) tumour (p < 0.001).
Tumour characteristics are summarized in Table II. 
The most common location of cSCC was the face (ex-
cluding ears, lips and eyelids), accounting for 50% of 
all cases. The proportion of facial cSCC, out of all the 
cSCCs, increased with age: among patients 85 years or 
older 63% of tumours were located on the face. Total 
of 12% of the cSCC were located on the upper extre-
mity, which was the second most frequent location. The 
Fig. 1. Annual number and crude incidence (per 100,000 persons) of 
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Fig. 2. Annual incidence (per 100,000 persons) of cutaneous squamous 
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location of tumours was different in men and women 
(p < 0.001). A total of 9.4% of cSCCs were located on the 
ear, of which 93% were in men. Scalp, neck and trunk 
were more commonly affected in men than in women. 
The number of tumours on the face increased over 
the study period with the annual incidence (per 100,000 
persons) increasing from 8.9 in 2006 to 13.8 in 2015. The 
incidence of trunk cSCC increased from 0.6 in 2006 to 
1.8 in 2015, and, the annual proportion of trunk cSCCs 
out of all cSCCs increased from 3.4% to 6.3%. Con-
versely, the annual proportion of cSCC of lip and lower 
extremity declined from 5.7% in 2006 to 0.7% in 2015 
and 9.1% in 2006 to 4.9% in 2015, respectively. There 
was an overall increasing trend of cSCCs over the study 
period (p = 0.018) but no statistically significant change 
in any specific localisation of tumours.
The majority of cSCCs were well differentiated (46%). 
Patients with a well-differentiated cSCC were 4 years 
younger than those with a poorly differentiated cSCC 
(median age 79; IQR 71–85 and 83; 77–88, p < 0.001). 
The tumour differentiation showed a small but not sta-
tistically significant (p = 0.301), shift from poorly to well 
differentiated. In 2006 tumours were well differentiated 
in 42.0% and poorly in 10.2% of cases, while in 2015 they 
were  well differentiated in 52.1% and poorly in 6.3% 
of cases. Most tumours (32%) had an invasion depth 
of 2 mm or less, although information on the depth of 
invasion was available in only 60% of the cases. During 
the study period the coverage of invasion depth data was 
improved from 35% in 2006 to 66% in 2015. 
All the cSCCs were treated with excision to achieve 
the macroscopic resection margins recommended by the 
international guidelines. Lateral resection margins were 
on average larger (median 4 mm, range 0–30) than the 
deepth resection margins (median 2 mm, range 0–20), 
although 31.6% and 42.0%, respectively, of these data 
were not mentioned in mm in the pathology reports or 
there was only scar or premalignant changes left in the 
final resection (definite margins could not be identified).
Adjuvant radiotherapy was used in 76 (6.7%) cases. 
Radiotherapy was used in 4.2% of well differentiated 
and 19.1% of poorly differentiated cSCC cases. In the 
majority of radiotherapy-treated cSCCs the depth of 
invasion was over 4 mm (in 24 out of 40 cases where 
invasion depth data was available on the pathology re-
port). Radiological imaging was performed for 61% of all 
cSCC patients. Ultrasonography was the most commonly 
used imaging technique (430 patients). Chest X-ray was 
used in 363 patients and computed tomography in 86 
patients. Radiological imaging was performed in 51% 
of well differentiated cSCC cases, compared to 74% of 
poorly differentiated cases.
DISCUSSION
This study shows that the annual number and crude inci-
dence of cSCC increased during the 10-year study period. 
The actual number of cSCC cases obtained, represented 
a true reflection of the workload, since each case was 
verified by reviewing the medical records and multiple 
tumours of the same patient were taken into account. This 
increase is in line with the results of previous studies in 
other countries (4, 8, 11–13), although differences in 
data collection methods mean that the numbers cannot 
be directly compared (4, 14).
The incidence of cSCC increased with age, being 
highest among those over 80 years old. Patients with a 
poorly differentiated cSCC were in mean 4 years older at 
the time of diagnosis than those with a well-differentiated 
cSCC. Like many other societies, Finland is facing the 
challenges of an aging population since the proportion 
of persons aged ≥ 65 years is estimated to rise from the 
present 20% to 29% by 2060 (15). This will lead to an 
older patient population with an increased risk of skin 





n = 394 (51%)
n (%)
Women
n = 380 (49%)
n (%)
Age
< 60 years 35 (4.5) 21 (5.3) 14 (3.7)
60–69 years 84 (10.9) 61 (15.5) 23 (6.1)
70–79 years 238 (30.7) 135 (34.3) 103 (27.1)
80–89 years 323 (41.7) 151 (38.3) 172 (45.3)
≥ 90 years 94 (12.1) 26 (6.6) 68 (17.9)
Immunosuppression
No 693 (89.5) 344 (87.3) 349 (91.8)
Yes 81 (10.5) 50 (12.7) 31 (8.2)
Number of squamous cell carcinoma tumours
1 588 (76.0) 294 (74.6) 294 (77.4)
2 116 (15.0) 61 (15.5) 55 (14.5)
3 42 (5.4) 18 (4.6) 24 (6.3)
4 14 (1.8) 11 (2.8)   3 (0.8)
5–9 11 (1.4)   7 (1.8)   4 (1.1)
≥ 10   3 (0.4)   3 (0.8)   0 (0)











Lip 52 (4.6) 31 (5.0) 21 (4.1)
Eyelid 11 (1.0)   5 (0.8)   6 (1.2)
Ear 106 (9.4) 99 (16.1)   7 (1.4)
Face 564 (49.9) 245 (39.9) 319 (61.7)
Scalp and neck 91 (8.0) 60 (9.8) 31 (6.0)
Trunk 61 (5.4) 51 (8.3) 10 (1.9)
Upper extremity 136 (12.0) 76 (12.4) 60 (11.6)
Lower extremity 68 (6.0) 30 (4.9) 38 (7.4)
Anogenital area 31 (2.7) 13 (2.1) 18 (3.5)
Oral cavity 11 (1.0)   4 (0.7)   7 (1.4)
Tumour differentiation  
Well 521 (46.1) 287 (46.7) 234 (45.3)
Moderate 450 (39.8) 248 (40.4) 202 (39.1)
Poorly 89 (7.9) 44 (7.2) 45 (8.7)
Unknown 71 (6.3) 35 (5.7) 36 (7.0)
Invasion depth  
< 1 mm 45 (4.0) 22 (3.6) 23 (4.4)
1.0–2.0 mm 313 (27.7) 166 (27.0) 147 (28.4)
2.1–4.0 mm 203 (17.9) 120 (19.5) 83 (16.1)
> 4.0 mm 112 (9.9) 63 (10.3) 49 (9.5)
























































415Cutaneous squamous cell carcinoma in Finland
Acta Derm Venereol 2019
cancer and an increased workload for the dermatological 
health services (6, 7) and multiprofessional skin cancer 
team, which is often required (7). 
During the study period, one fourth of patients had 
more than one cSCC and one tenth had been treated for 
cSCC before the study period. The mean risk of deve-
loping a subsequent cSCC within 3 years of the initial 
diagnosis has been estimated to be 18% (range 9–23%) 
(16) and 30–50% of patients with cSCC will develop 
another one within 5 years (17). The strongest predictors 
of future risk of keratinocyte carcinoma (cSCC and 
basal cell carcinoma), are a past history of an excised 
skin cancer and high age (18). In one study, the majority 
(67%) of patients with keratinocyte carcinoma who un-
derwent a whole body skin examination had additional 
lesions requiring treatment (19). Currently there is no 
standardised follow-up schedule for patients with cSCC 
but the European Dermatology Forum (EDF), the Eu-
ropean Association of Dermato-Oncology (EADO) and 
the European Organization of Research and Treatment of 
Cancer (EORTC) consensus group proposes follow-up 
clinical examinations annually for 5 years even for pa-
tients with a low risk cSCC (17), imposing considerable 
demands on dermatological services.
In our study, most cSCCs were located in sun-exposed 
areas, such as the face and upper extremity. Cumulative 
lifetime exposure to ultraviolet (UV) radiation from the 
sun is the principal risk factor for the development of 
cSCC (14, 20). In our study, there was no statistically 
significant change in the localisation of tumours during 
the study period, but the annual proportion of trunk 
cSCCs to all cSCCs increased during the study period. 
The same observation has been reported in other Nordic 
countries (11, 21). This may reflect the increased UV 
radiation exposure of the trunk as a result of changed 
tanning habits (fewer clothes, intentional outdoor tan-
ning, sunbed use), implying lying postures and changes 
in fashion trends (11, 21). A notable difference between 
men and women was observed in the localisation of cSCC 
concerning the ear, scalp and neck, possibly related to 
sex differences in hair coverage (22, 23). 
Depth of invasion and microscopic surgical resection 
margins in mm were often not mentioned in the pathology 
reports or definite margins could not be identified. Deep 
resection margins were generally smaller than lateral 
resection margins. Tumour depth is of great importance 
in identifying high risk cSCC and should be reported in 
all cases (24). Changes have already been made in our 
pathology laboratory to improve the histopathological 
information by modifying the structure of the pathology 
report form. The incomplete excision rate of cSCC ranges 
between 6–16% and the authors of a prospective obser-
vational study on incomplete excisions recommend more 
careful tumour markings and using deeper margins (25).
During the study period the degree of differentiation 
in cSCCs showed a minor shift from poorly to well dif-
ferentiated. This may be a reflection of earlier detection of 
cSCC during recent years of the study period. However, 
approximately 48% of cases were moderately to poorly 
differentiated which is a high risk feature of cSCC (17).
Limitations
The study has several limitations. Due to the retrospec-
tive nature of the study, it was not possible to collect all 
relevant information of the cSCCs, including the clinical 
diameter of the tumours. The cohort was drawn from 
a single hospital, although this indicates that all cases 
of cSCC in the geographical area of the hospital were 
probably included.
Conclusion
The incidence of cSCCs is increasing, especially in 
older patients. CSCCs are a future challenge, meaning 
that more and older patients may require treatment by 
a multiprofessional skin cancer team. Considering that 
patients may have multiple tumours, are at risk to develop 
new SCCs and also other additional skin cancers may 
be found, it is extremely important to examine patients’ 
whole body at the follow-up visits (16, 17, 19). Prophy-
lactic measures, such as, education on sun avoidance 
and protection, and early detection and intervention are 
necessary in order to reduce the development of more 
invasive cSCCs (14, 17). 
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